🔗 Share this article

The Nobel Prize in medical science has been awarded for revolutionary discoveries that illuminate how the body's defense network targets dangerous pathogens while sparing the healthy tissues.

A trio of renowned researchers—from Japan Shimon Sakaguchi and US scientists Dr. Brunkow and Dr. Ramsdell—received this honor.

The work uncovered specialized "sentinels" within the defense system that eliminate rogue immune cells that could attacking the organism.

The findings are now enabling innovative treatments for immune disorders and malignancies.

The winners will share a monetary award worth 11m SEK.

Decisive Findings

"The research has been decisive for comprehending how the immune system operates and the reason we don't all suffer from serious self-attack conditions," stated the head of the Nobel Committee.

This trio's research address a fundamental mystery: How does the immune system defend us from countless invaders while leaving our own tissues intact?

Our immune system employs immune cells that search for indicators of infection, including pathogens and germs it has never encountered.

Such defenders utilize detectors—called recognition units—that are produced by chance in countless variations.

That provides the defense network the ability to fight a broad range of threats, but the randomness of the mechanism unavoidably produces white blood cells that can target the body.

Security Guards of the Immune System

Scientists earlier understood that a portion of these harmful white blood cells were eliminated in the immune organ—the site where white blood cells develop.

This year's Nobel Prize honors the identification of regulatory T-cells—known as the body's "peacekeepers"—which travel through the system to disarm any immune cells that assault the body's own tissues.

It is known that this mechanism fails in self-attack conditions such as juvenile diabetes, MS, and RA.

The prize committee added, "These discoveries have established a novel area of research and spurred the development of innovative therapies, for example for tumors and autoimmune diseases."

In malignancies, regulatory T-cells prevent the system from fighting the tumor, so studies are focused on reducing their numbers.

In autoimmune diseases, trials are testing boosting T-reg cells so the body is not under attack. A comparable approach could also be useful in reducing the risks of organ transplant rejection.

Pioneering Experiments

Prof Shimon Sakaguchi, from a Japanese institution, performed tests on mice that had their immune gland removed, causing self-attack conditions.

The researcher demonstrated that introducing defense cells from healthy animals could prevent the disease—implying there was a system for preventing defenders from attacking the body.

Dr. Brunkow, affiliated with the a research center in Seattle, and Dr. Ramsdell, currently at Sonoma Biotherapeutics in San Francisco, were investigating an genetic immune disorder in rodents and humans that resulted in the discovery of a genetic factor vital for how T-regs function.

"The pioneering work has uncovered how the immune system is kept in check by regulatory T cells, preventing it from accidentally targeting the body's own tissues," said a prominent physiology specialist.

"The research is a remarkable example of how basic biological study can have broad consequences for public health."